Spots Global Cancer Trial Database for er positive
Every month we try and update this database with for er positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | NCT02549430 | Breast Cancer | Palbociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Fondazione Sandro Pitigliani | |
| A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer | NCT05909397 | Breast Cancer | ARV-471 (PF-078... Palbociclib Letrozole Palbociclib | 18 Years - | Pfizer | |
| A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | NCT05080842 | Breast Cancer | AC682 | 18 Years - | Accutar Biotechnology Inc | |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | NCT06247995 | Breast Cancer | [68Ga]Ga-NeoB [177Lu]Lu-NeoB Capecitabine | 18 Years - | Novartis | |
| Vaccination of Triple Negative Breast Cancer Patients | NCT02938442 | Triple Negative... Breast Neoplasm... | P10s-PADRE with... Doxorubicin + C... | 18 Years - | University of Arkansas | |
| AKT Inhibitor in Oestrogen Positive Breast Cancer | NCT02077569 | Invasive Breast... | AZD5363 | 18 Years - | University of Nottingham | |
| AKT Inhibitor in Oestrogen Positive Breast Cancer | NCT02077569 | Invasive Breast... | AZD5363 | 18 Years - | University of Nottingham | |
| A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS | NCT04852419 | Breast Neoplasm... | ZN-c5 | 18 Years - | Zentera Therapeutics HK Limited | |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | NCT06247995 | Breast Cancer | [68Ga]Ga-NeoB [177Lu]Lu-NeoB Capecitabine | 18 Years - | Novartis | |
| Vaccination of Triple Negative Breast Cancer Patients | NCT02938442 | Triple Negative... Breast Neoplasm... | P10s-PADRE with... Doxorubicin + C... | 18 Years - | University of Arkansas | |
| A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer | NCT01808040 | Post Menopausal... | TAK700 | 18 Years - | University of Wisconsin, Madison | |
| Effects of Aromatase Inhibitor Therapy on Muscle Function | NCT03581552 | Breast Cancer Breast Cancer F... | 18 Years - | Indiana University | ||
| A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer | NCT01808040 | Post Menopausal... | TAK700 | 18 Years - | University of Wisconsin, Madison | |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | NCT03250676 | Breast Neoplasm... Breast Cancer Estrogen-recept... Cancer, Breast Breast Cancer F... Breast Adenocar... Estrogen Recept... ER Positive | H3B-6545 | 18 Years - | Eisai Inc. | |
| A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer | NCT05909397 | Breast Cancer | ARV-471 (PF-078... Palbociclib Letrozole Palbociclib | 18 Years - | Pfizer | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | NCT05104866 | Breast Cancer | Dato-DXd Capecitabine Gemcitabine Eribulin Vinorelbine | 18 Years - | AstraZeneca | |
| AZD9833 China PK Study | NCT04818632 | ER+, HER2-, Met... | AZD9833 AZD9833 AZD9833 with pa... AZD9833 with ev... | 18 Years - 130 Years | AstraZeneca | |
| Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer | NCT01463007 | Breast Cancer | Accelerated par... Extended Follow... | 50 Years - | Brown University | |
| Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer | NCT00546156 | Breast Cancer | Doxorubicin Cyclophosphamid... Paclitaxel Bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer | NCT01808040 | Post Menopausal... | TAK700 | 18 Years - | University of Wisconsin, Madison |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
